Spots Global Cancer Trial Database for post essential thrombocythemia myelofibrosis
Every month we try and update this database with for post essential thrombocythemia myelofibrosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | NCT04551066 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | NCT04551053 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation |